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Primary splenic angiosarcoma is extremely rare but aggressive malignant vascular neoplasm. Here, we report a case
of vascular tumor in spleen that was initially misinterpreted as hemangioma. Two years after splenectomy, the patient
admitted again with aggravated abdomen pain and severe anemia. The magnetic resonance imaging (MRI) scan
showed widely metastases. The ensuing biopsy for lesion both in liver and in bone marrow showed the similar
pathological findings as that in spleen, which supported the final diagnosis of well-differentiated splenic angiosarcoma
with extensive metastases. The patient was dead in 3 months after discharge without chemotherapy. The copy
number changes for spleen lesion detected by array comparative genome hybridization showed copy number
gain at 11q23.2, 11q24.3, 12q24.33, 13q34, copy number loss at 1q24.2-q31.3, 1q41-q42.2, 1 q42.3-q43, 2q36.3-q37.3,
2q37.7, 3q13.33-q26.2, 3q28 - q29, 9p11.2, 13q11, 15q11, homozygous copy loss at 8p11.22, 22q11.23. Less than 200
cases of splenic angiosarcoma have been published in literature of English. To the best of our knowledge, this is the
first time analyzed cytogenetic alteration in a well-differentiated primary splenic angiosarcoma.
Keywords: Angiosarcoma, Well-differentiation, Splenectomy, Array comparative genomic hybridization, Copy number
changeBackground
Primary splenic angiosarcoma (PSA) is a rare malignant
neoplasm of endothelial cell, originating from vascular
or lymphatic. PSA was first reported by Langhans in
1879. To date, no more than 200 cases of splenic angio-
sarcoma have been reported in literature [1]. The
morphology features for this tumor are often uncharac-
teristic, ranging from well-formed anastomosing vessels
to high-grade epithelioid or spindled cells without clear
vasoformation [2]. Moreover, multiple appearances can
be seen in the same case, making great challenge for
diagnosis. However, no comprehensive research of* Correspondence: weihangma2014@126.com
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In this article, we describe a 38-year-old female
patient of malignant vascular tumor that was initially
interpreted as benign hemangioma in spleen with sub-
tle cytological atypia and died 2 years later for multiple
organ metastases. At the same time, we provided fur-
ther array comparative genome hybridization (aCGH)
analysis to make a preliminary exploration on the earlier
identification of subgroup of angiosarcoma. To date,
on cytogenetic analysis specific for primary splenic
angiosarcoma has been reported.Case presentation
A 38-year-old female patient was admitted to the hospital
after suffering upper abdomen pain and fatigue for about
1 week in 2011. She has no history of smoking and alcohol
or drug abuse. The patient denied immunodeficiency, his-
tory of malignancy and toxin exposure, and familyistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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tomography (CT) (Fig. 1) has been performed for fur-
ther examination. The result showed splenomegaly with
multifocal low-density lesions. Other organs including
liver, pancreas, renal, and adrenal were normal. Consid-
ering possibility of splenic neoplasm, and for further
clarification, splenectomy was carried out. Histopath-
ology (Fig. 2) evaluation showed well-formed anasto-
mosing vessel channels and proliferated endothelial cell
with mild atypia but inconspicuously malignant. Immu-
nohistochemistry (Fig. 2) revealed positive staining of
CD31and CD34 but negative staining of factor VIII,
CD68, p53. The pathology findings supported the diagno-
sis of hemangioma. Although no necrosis or hemorrhage
was found in macroscopic and histological examin-
ation, in consideration of splenomegaly and anasto-
mosing capillary-sized vessels, the well-differentiated
angiosarcoma cannot be excluded. After splenectomy,
the patient was quickly relieved from the pain and dis-
charged without any postoperative complications. Then,
the patient got lost to follow-up.
Two years after splenectomy in December 2013, the
patient presented with worsening upper abdomen pain,
fatigue, and frequent dizziness for 3 months. On phys-
ical examination, she showed severe anemic appear-
ance. There were no clinically palpable node and no
papilledema. There was no evidence of bruising andFig. 1 Abdomen CT scan in 2011 (a, b) demonstrated splenomegaly and m
are normal. The MRI in 2013 presented multiple cystic lesions in different s
signal, with high signal intensity on T2-weighted image (T2WI, c) and diffu
central low signal intensity were suspected intertumoral hemorrhage. Nodule
accessory spleen (arrow)easy bleeding. The initial lab tests were as follows: low
hemoglobin (45 g/L, normal range 113–151), an increase
of D-dimer, 78,700 ug/L (normal range 0–700ug/L), and a
mild increase of aspartate aminotransferase (AST), 48 U/L
(normal range 8–40U/L). Further examination of upper
abdominal magnetic resonance imaging (MRI) was imple-
mented. The result (Fig. 3) showed multiple nodes in the
liver and accessory spleen with rich blood supply and
signals of intratumoral hemorrhage. With these find-
ings in MRI, fine-needle biopsy was obtained of the
hepatic lesions. Due to further clarification of anemia,
bone marrow trephine biopsy as well as smear for cyto-
logical examination were performed. The pathology
evaluation (Fig. 2) on hepatic demonstrated a small
amount of proliferated endothelial cells. The result of
pathology findings of bone marrow biopsy (Fig. 2)
showed anastomosing vascular channels, proliferated
endothelial cells with few mitotic figures and mild nu-
clear atypia. The similarity of pathological findings in
the liver, spleen, and bone marrow and clinical image
presentation supported that the final diagnosis was
well-differentiated angiosarcoma of the spleen with
bone and liver metastasis. The patient was initially
treated with analgesia and blood transfusion. Because
few data can be acquired to guide chemotherapy and
poor therapeutic effect, she gave up further chemother-
apy after discussing with her family members. She wasultiple irregular low-density lesions. Liver, renal, adrenal, and pancreas
izes diffused in liver. The lesions displayed as inhomogeneous mixed
sion-weighted image (DWI, d). Some lesions that indicated eccentric or
lesion with abnormal sign as that in the liver was also found in remnant
Fig. 2 Tumor in spleen shows well-formed anastomosing vessel channels (a, HE 100×), proliferated endothelial cells with mild atypia (b, HE 400×),
immunohistochemistry revealed positive staining of CD31 (c, 100×) and CD34 (d, 100×). Tumor cells from bone biopsy showed anastomosing vessel
channels with proliferated endothelial cells without obvious malignant as that in spleen (e, HE 100×; f, HE 400×). Tumor cells from liver biopsy showed
a handful of endothelial cells without obvious malignant (g, HE 100×)
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and fatigue. Follow-up showed she passed away 3 months
after discharge.
DNA was extracted from ten 20-μm thick ribbons of
paraffin-embedded tumor of spleen from FFPE tissue
blocks using DNeasy Blood &Tissue Kit (Cat#69506,
QIAGEN, GmBH, Germany), following the manufac-
turer’s instructions. A total of 80 ng sample of DNA was
sent for processing via OconScanTM FFPE Express 2.0
service as manufacturer’s instructions. The OncoScan
assay contains more than 300,000 copy number and single
nucleotide polymorphism (SNP) oligonucleotide probes
with a median probe spacing of 4200 kb, with 541 somaticFig. 3 Summary of chromosomes copy number changes of splenic angios
copy number gains and red color on the left side represents copy numbermutations for known cancer genes. The arrays were
scanned by GeneChip® Scanner 3000 (Cat#00-00212,
Affymetrix, Santa Clara, CA, USA) and Command
Console Software 3.1 (Affymetrix, Santa Clara, CA, USA)
with default settings. Raw data that passed quality control
were further analyzed by Affymetrix® OconScan Analysis
Suite (Affymetrix, Santa Clara, CA, USA).
Statistical analysis of the CGH data was performed
by FASST2 Segmentation method. In order to adjust
the sensitivity of the segmentation algorithm, we de-
termined the significant threshold at 1.0E-8, specified
1000 kb being max contiguous probe spacing. The
minimum number of probes per segment required toarcoma detected by aCGH. The blue color on the right side represents
losses
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defined at ±3 × SD of all probes, and the threshold
was adjusted at ±0.5 for both.
Copy number change of this angiosarcoma of spleen
sample showed diverse DNA copy number alterna-
tions including copy number loss, copy number gain,
and homozygous copy loss. The copy number changes
were summarized in Fig. 3 and Table 1. The result
(Fig. 4 and Table 1) revealed that copy number gain
at 11q23.2, 11q24.3, 12q24.33, 13q34, copy number
loss at 1q24.2-q31.3, 1q41-q42.2, 1 q42.3-q43, 2q36.3-
q37.3, 2q37.7, 3q13.33-q26.2, 3q28-q29, 9p11.2, 13q11,
15q11, homozygous copy loss at 8p11.22, 22q11.23.
We found that a total of 1067 genes were affected
by copy number changes according to the result of
aCGH. In order to discuss the probably functions of
altered genes, 397 out of 1067 genes with known bio-
logical functions, we used the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID)
v6.7 (free online bioinformatics resources at http://
david.abcc.ncifcrf.gov/) to clustered Gene Ontology (GO)
group. The enriched GO groups (Fig. 4) were ranked ac-
cording to statistical significance measured by EASE score
(EASE score = −LgP), a modified Fish’s exact p value. The
result illustrates that five relevant pathways have been af-
fected by copy number changes as EASE score upper than
0.1. It is noteworthy that renin-angiotensin system and
ECM-receptor interaction pathways exhibit statistically
EASE score (p < 0.05).Table 1 Chromosomes copy number changes of splenic angiosarco
Chromosome Location Evens
(a) Copy number (CN) loss or homozygous copy loss
chr1 q24.2-q31.3 CN loss
chr1 q41- q42.2 CN loss
chr1 q42.3-q43 CN loss
chr2 q36.3-q37.3 CN loss
chr2 q37.7 CN loss
chr3 q13.33-q26.2 CN loss
chr3 q28-q29 CN loss
chr8 p11.22 Homozygous co
chr9 p11.2 CN loss
chr13 q11 CN loss
chr15 q11.1 CN loss
chr22 q11.23 Homozygous co
(b) Copy number gain
chr11 q23.2 CN gain
chr11 q24.3 CN gain
chr12 q24.33 CN gain
chr13 q34 CN gainDiscussion
Angiosarcoma, an extremely rare vascular malignant
tumor, approximately composes 2 % of all soft tissue
sarcoma. The incidence rate has risen over the past
30 years with unclear causes [3, 4]. PSA is the rare
type of angiosarcoma. A tumor distribution analysis of
543 patients with angiosarcoma indicated PSA account for
2.5 % [3]. Clinical manifestation among PSA patient is
variable and unspecific. Abdominal pain, weakness or fa-
tigue, fever, chest pain, and/or weight loss, anemia, and
thrombocytopenia were relatively predominant clinical
presentation. Another, the sign related to metastasis like
short of breath and gastrointestinal bleeding also can be
the starting clinical manifestation when a patient was ad-
mitted [5–8]. Splenomegaly was commonly depicted in
physical examination, and it can even be the only finding
[6]. Some patients presented with celiac hemorrhage due
to spontaneous splenic rupture, which occurred 13–32 %
in the literature [6, 9]. Chemotherapeutic efficacy is still
unclear but splenectomy as early as possible in people
without metastasis may prolong period of survival [10].
Early metastasis was often taken place in high inci-
dence with mostly involved in liver, bone marrow, lung,
and lymph nodes. Aggressive progress and early metas-
tasis always lead to dismal prognosis in patients with
PAS. Unfortunately, histological findings cannot fully
predict its malignant clinical behavior that even with
brisk atypical histological changes may present meta-
static lesions [11, 12]. Molecular tests have long beenma

















Fig. 4 Gene ontology groups enriched by genes with copy number losses and gains. EASE score higher than 0.1 has been listed in the figure. The
gene functional analysis revealed enrichments for otology terms related to diverse pathways, involved renin-angiotensin system and ECM-receptor
interaction pathways signaling pathways
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etic information on chromosomal abnormal on angiosar-
comas are limited. In most cases, cytogenetic analysis
indicated complex karyotypes, and the specific aberration
characteristics for tumor development and behavior have
far not been identified [13]. Gains in 8q and 20p and
losses in 22q are the most frequent chromosomes im-
balances among angiosarcomas [14]. But it should be
kept in mind that the angiosarcomas in different ana-
tomical sites or in different clinical settings might be
based on distinguishing gene-expression profiling. A
novel (1:14) (p21:q24) translocation has been reported
in a primary bone angiosarcoma [15]. Cluster analysis
of aCGH has identified two subgroup of primary bone
angiosarcoma: a group with a complex genetic profile
and a group with only few genetic aberrations [16].
Recent studies have shown that high-level amplification of
MYC oncogene on chromosome 8q24.21 is specific for
secondary angiosarcoma after radiation or lymphedema
[17]. Co-amplification of FLT4 (encoding VEGFR3) on
5q35 was detected in 25 % of radiation-induced angiosar-
coma [18]. Both FLT4 and MYC gene abnormalities can
potentially be used as molecular diagnostic tool to distin-
guish from atypical vascular lesions (AVL) and secondary
angiosarcoma [18, 19]. Loss of heterozygosity (LOH) of
WT-1, RB1, and P53 locus at chromosome region 11p13,
13q14, and 17p13, respectively, was reported in angiosar-
coma, supporting the role of those tumor suppressor
genes in pathogenesis of angiosarcoma [20].
In the present case, we applied Affymetrix Onco-
ScanTM FFPE Express molecular inversion probe
microarray platform to analyze the chromosome ab-
normal. The result in this case was the same as re-
ported elsewhere that angiosarcoma often displayed
complex chromosome aberration [13]. The previous
researches that benign vascular neoplasm often shows sim-
ple chromosome abnormality may support the malignantnature of the present case [21]. Notably, this observation
raises possibility that even well-differential angiosarcoma
may presents complex chromosome abnormality.
Aberration of 11q24.3 as seen in this case has reported
in several malignancy. But the molecular mechanism in
PAS remains unknown. Copy number gain in 11q24.3
may result in a constitutive high expression of ETS1 and
FLI1 genes. EST1 was found up-regulated a number of
angiogenic factors, such as vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF),
angiotensin II, endothelin-1, tumor necrosis factor-α
(TNF-α), or hydrogen peroxide. EST1 and FLI genes,
ETS transcription factors, have been proved to play a
significant role in malignancies [22, 23]. Conversely, in-
hibition of EST1 expression reduces the ability of endo-
thelial cells to migrate, to proliferate, or to adopt an
invasive behavior [23]. Strong expression of EST1 pro-
tein have been observed in angiosarcoma of skin, while
it weakens in hemangioma [24]. FLI expression is a
highly sensitive marker of a wide variety of common and
unusual vascular tumors, but it cannot distinguish be-
nign and malignant. A recent comprehensive study in
diffuse large B cell lymphoma showed copy number gain
in 11q24.3 and constructively up-regulates EST1 and
FLI genes, which contributes to the pathogenesis of dis-
ease [25]. However, the roles of 11q24.3 amplification in
PAS require further research both in molecular mechan-
ism and in large sample investigation.Conclusions
In summary, primary splenic angiosarcoma remains to
be a rare neoplasm with a high propensity for metas-
tasis. It is still different to diagnose according to histopath-
ology findings and immunohistochemistry profiles. But
combined with radiological manifestation and microscopic
examination, it may benefit to make final diagnosis.
Xu et al. World Journal of Surgical Oncology  (2015) 13:300 Page 6 of 6Cytogenetic analysis also gives some help to trace the ma-
lignant nature.
To the best of our knowledge, this is the first time that
cytogenetic alteration was analyzed in a well-differentiated
primary splenic angiosarcoma. However, the molecular
features to characterize this subgroup of angiosarcoma
need larger scale and more comprehensive study.
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